InJanuary 2021, the FDA approved CABENUVA to be administered every month to adults living with HIV-1. InFebruary 2022, the FDA approved an expanded label for CABENUVA to be administered every two months to ad...
The US FDA approval of long-acting cabotegravir and rilpivirine for use every two months is based on the global ATLAS-2M phase IIIb trial results, which demonstrated that every-two-month dosing was non-inferior to once-monthly dosing.2Non-inferiority was determined by ...
Cabenuva FDA approval is for HIV-1 treatment in patients 12 years of age and older and weighing at least 35 kg. Cabenuva is used to replace the current antiretroviral medications for patients who are virologically suppressed (HIV-1 RNA <50 copies/mL) and stable on antiretroviral medications, ...